AwardTape · Defense awards · Medical · Drugs and biologicals · HT941026AE002
HT941026AE002: $0 blanket purchase agreement to Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation holds a blanket purchase agreement from Defense Health Agency with $0 obligated since Oct 2023, against a ceiling of $5.0M. Latest action Feb 9, 2026.
Bpa for pluvicto and lutathera injection
| PIID | HT941026AE002 |
|---|---|
| Type | blanket purchase agreement |
| Company | Novartis Pharmaceuticals Corporation |
| Agency | Defense Health Agency |
| Contracting office | DEFENSE HEALTH AGENCY HCD WEST |
| Category | Medical · Drugs and biologicals |
| PSC | 6505 DRUGS AND BIOLOGICALS |
| NAICS | 325412 PHARMACEUTICAL PREPARATION MANUFACTURING |
| Obligated since Oct 2023 | $0 |
| Total obligated (lifetime) | $0 |
| Ceiling (base and all options) | $5.0M |
| Base date | Jan 29, 2026 |
| Latest action | Feb 9, 2026 |
| End date | n/a |
| Actions since Oct 2023 | 2 |
| Pricing | Set per order |
| Competition | Not reported |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
| Award | Company | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|---|
| HT941026FE027 BPA call | Novartis Pharmaceuticals Corporation | $206K | Pluvicto and lutathera injection | Defense Health Agency | Drugs and biologicals | Feb 11, 2026 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial